[en] The term "In Silico Trial" indicates the use of computer modelling and simulation to evaluate the safety and efficacy of a medical product, whether a drug, a medical device, a diagnostic product or an advanced therapy medicinal product. Predictive models are positioned as new methodologies for the development and the regulatory evaluation of medical products. New methodologies are qualified by regulators such as FDA and EMA through formal processes, where a first step is the definition of the Context of Use (CoU), which is a concise description of how the new methodology is intended to be used in the development and regulatory assessment process. As In Silico Trials are a disruptively innovative class of new methodologies, it is important to have a list of possible CoUs highlighting potential applications for the development of the relative regulatory science. This review paper presents the result of a consensus process that took place in the InSilicoWorld Community of Practice, an online forum for experts in in silico medicine. The experts involved identified 46 descriptions of possible CoUs which were organised into a candidate taxonomy of nine CoU categories. Examples of 31 CoUs were identified in the available literature; the remaining 15 should, for now, be considered speculative.
Disciplines :
Engineering, computing & technology: Multidisciplinary, general & others
Author, co-author :
Viceconti, Marco
Emili, Luca
Afshari, Payman
Courcelles, Eulalie
Curreli, Cristina
Famaey, Nele
Geris, Liesbet ; Université de Liège - ULiège > GIGA > GIGA In silico medecine - Biomechanics Research Unit
American Society of Mechanical Engineers (ASME). Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices. New York: American Society of Mechanical Engineers, 2018.
T. Colatsky et al., "The comprehensive in vitro proarrhythmia assay (CiPA) initiative-Update on progress," J. Pharmacological Toxicological Methods, vol. 81, pp. 15-20, Sep. 2016, doi: 10.1016/j.vascn.2016.06.002.
S. Gross-Hardt et al., "Low-flow assessment of current ECMO/ECCO2R rotary blood pumps and the potential effect on hemocompatibility," Crit. Care, vol. 23, no. 1, pp. 348, Nov. 2019, doi: 10.1186/s13054-019-2622-3.
J. Leedale et al., "A combined in vitro/in silico approach to identifying off-target receptor toxicity," iSci., vol. 4, pp. 84-96, Jun. 2018, doi: 10.1016/j.isci.2018.05.012.
M.-E. Oraiopoulou et al., "Integrating in vitro experiments with in silico approaches for glioblastoma invasion: The role of cell-to-cell adhesion heterogeneity," Sci. Rep., vol. 8, no. 1, Nov. 2018, Art. no. 1, doi: 10.1038/s41598-018-34521-5.
A. M. Poss et al., "Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease," J. Clin. Invest., vol. 130, no. 3, pp. 1363-1376, Mar. 2020, doi: 10.1172/JCI131838.
M. Cortesi, C. Liverani, L. Mercatali, T. Ibrahim, and E. Giordano, "An in-silico study of cancer cell survival and spatial distribution within a 3D microenvironment," Sci. Rep., vol. 10, no. 1, Dec. 2020, Art. no. 1, doi: 10.1038/s41598-020-69862-7.
F. Gianì, G. Russo, M. Pennisi, L. Sciacca, F. Frasca, and F. Pappalardo, "Computational modeling reveals MAP3K8 as mediator of resistance to Vemurafenib in thyroid cancer stem cells," Bioinf., vol. 35, no. 13, pp. 2267-2275, Jul. 2019, doi: 10.1093/bioinformatics/bty969.
S. C. Pingle et al., "In silico modeling predicts drug sensitivity of patientderived cancer cells," J. Transl. Med., vol. 12, no. 1, pp. 128, 2014, doi: 10.1186/1479-5876-12-128.
A. Mitsos, I. N. Melas, P. Siminelakis, A. D. Chairakaki, J. Saez-Rodriguez, and L. G. Alexopoulos, "Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data," PLoS Comput. Biol., vol. 5, no. 12, Dec. 2009, Art. no. e1000591, doi: 10.1371/journal.pcbi.1000591.
S. Chattopadhyay and R. K. Mahapatra, "Identification of adaptive inhibitors of cryptosporidium parvum fatty acyl-coenzyme a synthetase isoforms by virtual screening," Parasitol. Res., vol. 118, no. 11, pp. 3159-3171, Nov. 2019, doi: 10.1007/s00436-019-06445-0.
S. J. Sonntag et al., "Virtual implantations to transition from porcine to bovine animal models for a total artificial heart," Artif. Organs., vol. 44, no. 4, pp. 384-393, Apr. 2020, doi: 10.1111/aor.13578.
W. C. Chiu et al., "Device thrombogenicity emulation: An in silico predictor of in vitro and in vivo ventricular assist device thrombogenicity," Sci. Rep., vol. 9, no. 1, Feb. 2019, Art. no. 1, doi: 10.1038/s41598-019-39897-6.
C. Holman et al., "Where have all the rodents gone? The effects of attrition in experimental research on cancer and stroke," PLoS Biol., vol. 14, no. 1, Jan. 2016, Art. no. e1002331, doi: 10.1371/journal.pbio.1002331.
Y. Lu, M. Boudiffa, E. Dall'Ara, Y. Liu, I. Bellantuono, and M. Viceconti, "Longitudinal effects of parathyroid hormone treatment on morphological, densitometric and mechanical properties of mouse tibia," J. Mech. Behav. Biomed. Mater., vol. 75, pp. 244-251, Nov. 2017, doi: 10.1016/j.jmbbm.2017.07.034.
R. G. Diaza, S. Manganelli, A. Esposito, A. Roncaglioni, A. Manganaro, and E. Benfenati, "Comparison of in silico tools for evaluating rat oral acute toxicity," SAR QSAR Environ. Res., vol. 26, no. 1, pp. 1-27, 2015, doi: 10.1080/1062936X.2014.977819.
A. Palladini et al., "In silico modeling and in vivo efficacy of cancerpreventive vaccinations," Cancer Res., vol. 70, no. 20, pp. 7755-7763, Oct. 2010, doi: 10.1158/0008-5472.CAN-10-0701.
E. Passini et al., "Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity," Front. Physiol., vol. 8, 2017, Art. no. 668, doi: 10.3389/fphys.2017.00668.
D. Zink, J. K. C. Chuah, and J. Y. Ying, "Assessing toxicity with human cell-based in vitromethods," Trends Mol. Med., vol. 26, no. 6, pp. 570-582, Jun. 2020, doi: 10.1016/j.molmed.2020.01.008.
A. L. Komorowski, J.W. Mituś, M. A. Sanchez Hurtado, and F.M. Sanchez Margallo, "Porcine model in the laparoscopic liver surgery training," Pol. Przegl. Chir., vol. 87, no. 8, pp. 425-428, Aug. 2015, doi: 10.1515/pjs-2015-0083.
C. Boedecker et al., "Using virtual 3D-models in surgical planning: Workflow of an immersive virtual reality application in liver surgery," Langenbecks Arch. Surg., Mar. 2021, doi: 10.1007/s00423-021-02127-7.
T. C. Gasser, "Biomechanical rupture risk assessment: A consistent and objective decision-making tool for abdominal aortic aneurysm patients," Aorta (Stamford), vol. 4, no. 2, pp. 42-60, Apr. 2016, doi: 10.12945/j.aorta.2015.15.030.
J. Fiehler et al., "ERASER," Stroke, vol. 50, no. 5, pp. 1275-1278, Mar. 2019, doi: 10.1161/STROKEAHA.119.024858.
F. Gullo et al., "Computational modeling of the expansion of human cord blood CD133+ hematopoietic stem/progenitor cells with different cytokine combinations," Bioinformatics, vol. 31, no. 15, pp. 2514-2522, Aug. 2015, doi: 10.1093/bioinformatics/btv172.
T. Haddad, A. Himes, L. Thompson, T. Irony, and R. Nair "Incorporation of stochastic engineering models as prior information in Bayesian medical device trials," J. Biopharm. Stat., vol. 27, no. 6, pp. 1089-1103, 2017, doi: 10.1080/10543406.2017.1300907.
H. Lehrmann et al., "Novel electrocardiographic criteria for real-time assessment of anterior mitral line block: 'V1 jump' and 'V1 delay'," JACC Clin. Electrophysiol., vol. 4, no. 7, pp. 920-932, Jul. 2018, doi: 10.1016/j.jacep.2018.03.007.
J. M. Switchenko, A. L. Heeke, T. C. Pan, and W. L. Read, "The use of a predictive statistical model to make a virtual control arm for a clinical trial," PLoS One, vol. 14, no. 9, Sep. 2019, Art. no. e0221336, doi: 10.1371/journal.pone.0221336.
J. D. Drews et al., "Spontaneous reversal of stenosis in tissue-engineered vascular grafts," Sci. Transl. Med., vol. 12, no. 537, Apr. 2020, Art. no. eaax6919, doi: 10.1126/scitranslmed.aax6919.
N. Agrawal et al., "Use of simulation in plastic surgery training," Plast. Reconstr. Surg. Glob. Open., vol. 8, no. 7, Jul. 2020, doi: 10.1097/GOX.0000000000002896.
P. R. Konduri, H. A. Marquering, E. E. van Bavel, A. Hoekstra, C. B. L. M. Majoie and INSIST Investigators, "In-silico trials for treatment of acute ischemic stroke," Front Neurol., vol. 11, 2020, Art. 558125, doi: 10.3389/fneur.2020.558125.
R. Andlauer et al., "Influence of left atrial size on P-wave morphology: Differential effects of dilation and hypertrophy," Europace, vol. 20, no. suppl-3, pp. iii36-iii44, Nov. 2018, doi: 10.1093/europace/euy231.
S. Chabaud, P. Girard, P. Nony, and J.-P. Boissel, "Clinical trial simulation using therapeutic effect modeling: Application to ivabradine efficacy in patients with angina pectoris," J. Pharmacokinet Pharmacodyn, vol. 29, no. 4, pp. 339-363, Aug. 2002, doi: 10.1023/a:1020953107162.
